Helixmith Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 75
- Market Cap
- -
- Website
- http://helixmith.com
The Efficacy and Safety of TADIOS as an Adjuvant Therapy in Patients Diagnosed With Mild to Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- Drug: PlaceboDrug: TADIOS
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05552625
- Locations
- 🇮🇳
Sparsh Superspeciality Hospital, Bangalore, Karnataka, India
🇮🇳Vagus Super Specialty Hospital, Bangalore, Karnataka, India
🇮🇳Lakshmi Nursing Home, Cochin, Kerala, India
The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
- Conditions
- CMT
- Interventions
- Biological: Engensis (VM202)
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05361031
- Locations
- 🇰🇷
Samsung Medical Center, Seoul National University Hospital, Seoul, Korea, Republic of
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Biological: EngensisOther: Placebo
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05176093
- Locations
- 🇺🇸
Austin Neuromuscular Center, Austin, Texas, United States
🇰🇷Hanyang University Medical Center, Seoul, Korea, Republic of
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT04873232
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Clinical Trials - Little Rock, Little Rock, Arkansas, United States
🇺🇸California Medical Clinic for Headache, Los Angeles, California, United States
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04632225
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins University Department of Neurology, Baltimore, Maryland, United States
🇺🇸St. Joseph's Hospital and Medical Center, Barrows Neurological Institute, Phoenix, Arizona, United States
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Other: Placebo
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT04469270
- Locations
- 🇺🇸
Futuro Clinical Trials, LLC, McAllen, Texas, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Clinical Trials - Little Rock, Little Rock, Arkansas, United States
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
- Conditions
- Painful Diabetic NeuropathyDiabetic Neuropathy, Painful
- Interventions
- Genetic: Long-Term Follow-Up of Patients who Received Engensis (VM202)Drug: Long-Term Follow-Up of Patients who Received Placebo
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 101
- Registration Number
- NCT04055090
- Locations
- 🇺🇸
Neurological Research Institute, Santa Monica, California, United States
🇺🇸University of Florida McKnight Brain Institute, Gainesville, Florida, United States
🇺🇸Diablo Clinical Research, Inc., Walnut Creek, California, United States
Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea
- Conditions
- Acute Myocardial InfarctionIschemic Heart Disease
- Interventions
- Drug: Stage 2-PlaceboBiological: Stage 1-Middle dose VM202RYBiological: Stage 1-High dose VM202RYBiological: Stage 2-High dose VM202RYBiological: Stage 1-Low dose VM202RYBiological: Stage 2-Low dose VM202RYDevice: C-Cathez® Catheter
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT03404024
- Locations
- 🇰🇷
GangNeung Asan Hospital, Gangneung, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Ewha Womans University Medical Center, Seoul, Korea, Republic of
Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers
- Conditions
- Foot Ulcer, Diabetic
- Interventions
- Genetic: Engensis (VM202)Drug: Placebo
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT02563522
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸Sacramento Foot and Ankle, Carmichael, California, United States
🇺🇸USC Keck School of Medicine, Los Angeles, California, United States
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
- Conditions
- Painful Diabetic NeuropathyDiabetic Neuropathy, Painful
- Interventions
- Other: placeboBiological: Engensis (VM202)
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Helixmith Co., Ltd.
- Target Recruit Count
- 507
- Registration Number
- NCT02427464
- Locations
- 🇺🇸
Martin Foot and Ankle, York, Pennsylvania, United States
🇺🇸University of Florida McKnight Brain Institute, Gainesville, Florida, United States
🇺🇸Raleigh Neurology Associates, P.A., Raleigh, North Carolina, United States